41 related articles for article (PubMed ID: 33273854)
1. Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study.
Parry MG; Nossiter J; Sujenthiran A; Cowling TE; Patel RN; Morris M; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1219-1229. PubMed ID: 33279595
[TBL] [Abstract][Full Text] [Related]
2. Mobile-Based Application Interventions to Enhance Cancer Control and Care in Low- and Middle-Income Countries: A Systematic Review.
Donkor A; Ayitey JA; Adotey PN; Ofori EO; Kitson-Mills D; Vanderpuye V; Opoku SY; Luckett T; Agar MR; Engel-Hills P
Int J Public Health; 2023; 68():1606413. PubMed ID: 38125709
[No Abstract] [Full Text] [Related]
3. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of prostate specific antigen density and transrectal ultrasonography-guided biopsies in 100 consecutive patients with a negative digital rectal examination and intermediate serum prostate specific antigen levels.
Tarcan T; Ozveri H; Biren T; Türkeri L; Akdas A
Int J Urol; 1997 Jul; 4(4):362-7. PubMed ID: 9256325
[TBL] [Abstract][Full Text] [Related]
5. Development of Mobile Application for Dynamically Monitoring the Risk of Prostate Cancer and Clinicopathology.
Wang H; Chen L; Zhou J; Tai S; Liang C
Cancer Manag Res; 2020; 12():12175-12184. PubMed ID: 33273854
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
7. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
8. Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
[TBL] [Abstract][Full Text] [Related]
9. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Survival outcomes of radical prostatectomy and external beam radiotherapy in clinically localized high-risk prostate cancer: a population-based, propensity score matched study.
Gu X; Gao X; Cui M; Xie M; Ma M; Qin S; Li X; Qi X; Bai Y; Wang D
Cancer Manag Res; 2018; 10():1061-1067. PubMed ID: 29773955
[TBL] [Abstract][Full Text] [Related]
12. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers.
Paner GP; Stadler WM; Hansel DE; Montironi R; Lin DW; Amin MB
Eur Urol; 2018 Apr; 73(4):560-569. PubMed ID: 29325693
[TBL] [Abstract][Full Text] [Related]
13. Cancer statistics, 2018.
Siegel RL; Miller KD; Jemal A
CA Cancer J Clin; 2018 Jan; 68(1):7-30. PubMed ID: 29313949
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer.
Nordström T; Akre O; Aly M; Grönberg H; Eklund M
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):57-63. PubMed ID: 29259293
[TBL] [Abstract][Full Text] [Related]
15. Prognostic parameter for high risk prostate cancer patients at initial presentation.
Kato M; Kimura K; Hirakawa A; Kobayashi Y; Ishida R; Kamihira O; Majima T; Funahashi Y; Sassa N; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2018 Jan; 78(1):11-16. PubMed ID: 29094384
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
